Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of “Buy” from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $6.63.

Several equities analysts have commented on TSHA shares. Needham & Company LLC reissued a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, February 27th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, February 26th.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock opened at $1.20 on Friday. The firm’s 50 day simple moving average is $1.60 and its 200 day simple moving average is $1.85. The firm has a market capitalization of $246.00 million, a PE ratio of 1.90 and a beta of 0.96. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $2.02 million during the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. As a group, analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds have recently added to or reduced their stakes in the company. Octagon Capital Advisors LP raised its holdings in shares of Taysha Gene Therapies by 128.6% in the fourth quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company’s stock valued at $18,078,000 after acquiring an additional 5,877,778 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at about $8,650,000. Bank of America Corp DE boosted its stake in Taysha Gene Therapies by 1,178.9% during the 4th quarter. Bank of America Corp DE now owns 1,710,303 shares of the company’s stock worth $2,959,000 after purchasing an additional 1,576,568 shares during the last quarter. Norges Bank purchased a new position in Taysha Gene Therapies during the fourth quarter worth approximately $2,528,000. Finally, Avoro Capital Advisors LLC raised its position in shares of Taysha Gene Therapies by 7.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company’s stock valued at $34,600,000 after buying an additional 1,349,999 shares during the period. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.